Investigation of genetic loci shared between bipolar disorder and risk-taking propensity: potential implications for pharmacological interventions
- PMID: 34035470
- PMCID: PMC8280111
- DOI: 10.1038/s41386-021-01045-y
Investigation of genetic loci shared between bipolar disorder and risk-taking propensity: potential implications for pharmacological interventions
Abstract
Patients with bipolar disorder (BD) often show increased risk-taking propensity, which may contribute to poor clinical outcome. While these two phenotypes are genetically correlated, there is scarce knowledge on the shared genetic determinants. Using GWAS datasets on BD (41,917 BD cases and 371,549 controls) and risk-taking (n = 466,571), we dissected shared genetic determinants using conjunctional false discovery rate (conjFDR) and local genetic covariance analysis. We investigated specificity of identified targets using GWAS datasets on schizophrenia (SCZ) and attention-deficit hyperactivity disorder (ADHD). The putative functional role of identified targets was evaluated using different tools and GTEx v. 8. Target druggability was evaluated using DGIdb and enrichment for drug targets with genome for REPositioning drugs (GREP). Among 102 loci shared between BD and risk-taking, 87% showed the same direction of effect. Sixty-two were specifically shared between risk-taking propensity and BD, while the others were also shared between risk-taking propensity and either SCZ or ADHD. By leveraging pleiotropic enrichment, we reported 15 novel and specific loci associated with BD and 22 with risk-taking. Among cross-disorder genes, CACNA1C (a known target of calcium channel blockers) was significantly associated with risk-taking propensity and both BD and SCZ using conjFDR (p = 0.001 for both) as well as local genetic covariance analysis, and predicted to be differentially expressed in the cerebellar hemisphere in an eQTL-informed gene-based analysis (BD, Z = 7.48, p = 3.8E-14; risk-taking: Z = 4.66, p = 1.6E-06). We reported for the first time shared genetic determinants between BD and risk-taking propensity. Further investigation into calcium channel blockers or development of innovative ligands of calcium channels might form the basis for innovative pharmacotherapy in patients with BD with increased risk-taking propensity.
© 2021. The Author(s), under exclusive licence to American College of Neuropsychopharmacology.
Figures


Similar articles
-
Genome-wide analysis reveals genetic overlap between alcohol use behaviours, schizophrenia and bipolar disorder and identifies novel shared risk loci.Addiction. 2022 Mar;117(3):600-610. doi: 10.1111/add.15680. Epub 2021 Oct 3. Addiction. 2022. PMID: 34472679
-
Identification of genetic overlap and novel risk loci for attention-deficit/hyperactivity disorder and bipolar disorder.Mol Psychiatry. 2021 Aug;26(8):4055-4065. doi: 10.1038/s41380-019-0613-z. Epub 2019 Dec 2. Mol Psychiatry. 2021. PMID: 31792363
-
Genome-wide analyses reveal novel opioid use disorder loci and genetic overlap with schizophrenia, bipolar disorder, and major depression.Addict Biol. 2023 Jun;28(6):e13282. doi: 10.1111/adb.13282. Addict Biol. 2023. PMID: 37252880 Free PMC article.
-
Genetic associations between bipolar disorder and brain structural phenotypes.Cereb Cortex. 2023 May 24;33(11):6990-7000. doi: 10.1093/cercor/bhad014. Cereb Cortex. 2023. PMID: 36734292
-
A large-scale integrative analysis of GWAS and common meQTLs across whole life course identifies genes, pathways and tissue/cell types for three major psychiatric disorders.Neurosci Biobehav Rev. 2018 Dec;95:347-352. doi: 10.1016/j.neubiorev.2018.10.005. Epub 2018 Oct 16. Neurosci Biobehav Rev. 2018. PMID: 30339835 Review.
Cited by
-
Bidirectional genetic overlap between bipolar disorder and intelligence.BMC Med. 2022 Nov 30;20(1):464. doi: 10.1186/s12916-022-02668-8. BMC Med. 2022. PMID: 36447210 Free PMC article.
-
Dissecting the genetic overlap between severe mental disorders and markers of cellular aging: Identification of pleiotropic genes and druggable targets.Neuropsychopharmacology. 2024 May;49(6):1033-1041. doi: 10.1038/s41386-024-01822-5. Epub 2024 Feb 24. Neuropsychopharmacology. 2024. PMID: 38402365 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical